0      0

2020 Annual Meeting


AM20-33 - AM20-33: COVID-19 Convalescent Plasma (CCP) -- The Regulatory Landscape


Oct 5, 2020 10:00am ‐ Oct 5, 2020 11:00am


Credits: None available.

Standard: $25.00
Members: $20.00

Description

During this live Q&A session, FDA’s Peter Marks and Nicole Verdun will answer questions about the regulatory framework for COVID-19 Convalescent Plasma (CCP). We will be taking live questions during the session and will try to get to as many of them as possible. 

Topics for discussion include:

- Timeline for implementation of the EUA.
- FDA’s use of temporary enforcement discretion .
- An update on the testing and labeling collections as high-titer or low-titer.
- Inventory management options such as retesting units collected under the National Expanded Access 

Program for use under the EUA or for shipment to the Surge Capacity Storage

Learning Objectives:
  • Review current regulatory process for CCP
  • Describe current regulations regarding CCP
  • Describe current regulatory landscape for CCP

Speaker(s):

Credits Available


AM20-33: COVID-19 Convalescent Plasma (CCP) -- The Regulatory Landscape Evaluation

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content